Line 790: | Line 790: | ||
<svg height="auto" width="100%" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewbox="0 0 1200 3000"> | <svg height="auto" width="100%" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewbox="0 0 1200 3000"> | ||
<image height="3000px" width="1200px" xlink:href="https://static.igem.org/mediawiki/2017/7/71/KU_Leuven-homepage.svg"></image> | <image height="3000px" width="1200px" xlink:href="https://static.igem.org/mediawiki/2017/7/71/KU_Leuven-homepage.svg"></image> | ||
− | <path style="fill:none;stroke:#cc3333;stroke-width:6;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:4;stroke-opacity:1;stroke-dasharray:8000;stroke-dashoffset:0" data- | + | <path style="fill:none;stroke:#cc3333;stroke-width:6;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:4;stroke-opacity:1;stroke-dasharray:8000;stroke-dashoffset:0" data-5000-end="stroke-dashoffset:0;" data-5000-top="stroke-dashoffset:8000;" d="M1180,0v600h-90l-12.5-37.5l-12.5,75l-12.5-37.5H20v650l180,1.5c57.7-0.2,57.4,98.8,114.5,98.5c56.9,0,56.3-98.8,114.1-99c57.7-0.2,57.4,98.8,114.5,98.5c56.9,0,56.3-98.8,114.1-99c57.7-0.2,57.4,98.8,114.5,98.5c56.9,0,56.3-98.8,114.1-99c57.7-0.2,57.4,100.2,114.2,100h175v100l25,7.5l-50,10l25,7.5v475H600v450l200-100l-200,100l200,100l-200-100l-200,100l200-100l-200-100"> |
</path> | </path> | ||
<a xlink:href="https://2017.igem.org/Team:KU_Leuven/Model"> | <a xlink:href="https://2017.igem.org/Team:KU_Leuven/Model"> |
Revision as of 11:28, 21 September 2017
KU Leuven
HEKcite
1
Project
Inspired by the heart
We drew our inspiration from the versatility and robustness of the heart. It beats continuously over the years, rapidly adapting its pace when necessary.
2
Research
Creation of the Rhythm
Given our knowledge about heart currents, we hypothesized it would be possible to recreate a steady rhythm in a non-excitable cell using only three ion channels.
3
Application
Biosensing
Finally, we aim to influence the pace by varying concentrations of biological effectors. Our main focus is establishing a new form of therapeutic drug monitoring.
4
Contact
Contact
5